What is Unicycive Therapeutics Inc's earnings per share (EPS)?

Unicycive Therapeutics Inc (UNCY) reported diluted earnings per share of $-5.65 for fiscal year 2025. This represents a -908.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Unicycive Therapeutics Inc Financials

UNCY

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Unicycive Therapeutics Inc (UNCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.78x

For every $1 of reported earnings, Unicycive Therapeutics Inc generates $0.78 in operating cash flow (-$28.6M OCF vs -$36.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-452.4x

Unicycive Therapeutics Inc earns $-452.4 in operating income for every $1 of interest expense (-$32.1M vs $71K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$32.1M

YoY+0.0%

Unicycive Therapeutics Inc's EBITDA was -$32.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.0% from the prior year.

Net Income

-$36.7M

YoY+0.0%

Unicycive Therapeutics Inc reported -$36.7M in net income in fiscal year 2025. This represents an increase of 0.0% from the prior year.

EPS (Diluted)

$-5.65

YoY-908.9%

Unicycive Therapeutics Inc earned $-5.65 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 908.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$28.6M

YoY+0.0%

Unicycive Therapeutics Inc generated -$28.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 0.0% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

25M

YoY+121.7%

Unicycive Therapeutics Inc had 25M shares outstanding in fiscal year 2025. This represents an increase of 121.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$20.0M

YoY+0.0%

5Y CAGR+81.5%

Unicycive Therapeutics Inc invested $20.0M in research and development in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$72K

YoY+0.0%

Unicycive Therapeutics Inc invested $72K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

UNCY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$675K-29.0%	$951K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.0M0.0%	$20.0M+55.1%	$12.9M+3.7%	$12.4M+104.5%	$6.1M+499.0%	$1.0M
SG&A Expenses	$12.1M0.0%	$12.1M+41.6%	$8.5M+2131.6%	$383K+56.3%	$245K+322.4%	$58K
Operating Income	-$32.1M0.0%	-$32.1M-54.6%	-$20.8M-15.1%	-$18.1M-101.1%	-$9.0M-344.4%	-$2.0M
Interest Expense	$71K0.0%	$71K-13.4%	$82K+1266.7%	$6K-99.0%	$628K+157.4%	$244K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$36.7M0.0%	-$36.7M-20.2%	-$30.5M-69.1%	-$18.1M-80.3%	-$10.0M-342.4%	-$2.3M
EPS (Diluted)	$-5.65-908.9%	$-0.56	$-1.28-6.7%	$-1.20-39.5%	$-0.86	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.0M+69.4%	$1.8M-19.4%	$2.2M	N/A	$3.0M-37.4%	$4.9M-28.5%	$6.8M	N/A
SG&A Expenses	$4.4M-16.0%	$5.2M-10.4%	$5.8M	N/A	$3.2M+26.6%	$2.5M+5.9%	$2.4M	N/A
Operating Income	-$7.3M-5.4%	-$7.0M+12.8%	-$8.0M	N/A	-$6.3M+15.5%	-$7.4M+19.6%	-$9.2M	N/A
Interest Expense	$15K+15.4%	$13K-13.3%	$15K	N/A	$15K-6.3%	$16K-20.0%	$20K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.0M+6.8%	-$6.4M-1231.1%	$570K	N/A	-$4.1M-141.6%	$9.9M+147.0%	-$21.0M	N/A
EPS (Diluted)	$-0.33+36.5%	$-0.52	$-0.05	N/A	$-0.46+69.3%	$-1.50-145.9%	$-0.61	N/A

UNCY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$31.7M+123.2%	$14.2M+403.6%	$2.8M-85.0%	$18.7M+9088.2%	$204K
Current Assets	N/A	$30.9M+131.0%	$13.4M+406.8%	$2.6M-85.6%	$18.4M+8925.0%	$204K
Cash & Equivalents	N/A	$26.1M+169.5%	$9.7M+2032.1%	$455K-97.3%	$16.6M	N/A
Inventory	N/A	N/A	N/A	$2.2M+19.5%	$1.8M	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$24.2M+34.6%	$18.0M+448.1%	$3.3M+45.3%	$2.3M-21.4%	$2.9M
Current Liabilities	N/A	$24.1M+37.6%	$17.5M+433.9%	$3.3M+56.0%	$2.1M-26.8%	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$7.4M+295.1%	-$3.8M-717.4%	-$466K-102.8%	$16.5M+717.1%	-$2.7M
Retained Earnings	N/A	-$101.3M-56.9%	-$64.5M-89.8%	-$34.0M-113.3%	-$15.9M-169.1%	-$5.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$50.6M+68.7%	$30.0M+7.3%	$27.9M-11.8%	$31.7M-17.9%	$38.6M-13.7%	$44.7M-14.7%	$52.4M+269.1%	$14.2M
Current Assets	$50.3M+70.3%	$29.5M+8.0%	$27.3M-11.6%	$30.9M-18.0%	$37.7M-14.3%	$44.1M-14.7%	$51.7M+285.7%	$13.4M
Cash & Equivalents	$42.7M+91.2%	$22.3M+12.9%	$19.8M-24.4%	$26.1M-19.2%	$32.3M-22.6%	$41.8M-14.6%	$48.9M+404.4%	$9.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.1M-3.2%	$13.6M-18.6%	$16.7M-31.2%	$24.2M-63.5%	$66.4M+11.5%	$59.5M-22.5%	$76.8M+326.9%	$18.0M
Current Liabilities	$13.1M-3.2%	$13.6M-18.6%	$16.7M-30.9%	$24.1M+130.6%	$10.5M-20.1%	$13.1M-56.8%	$30.3M+72.7%	$17.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37.5M+128.1%	$16.4M+45.8%	$11.3M+51.7%	$7.4M+126.7%	-$27.9M-87.6%	-$14.8M+39.3%	-$24.5M-542.1%	-$3.8M
Retained Earnings	-$113.2M-5.6%	-$107.1M-6.4%	-$100.7M+0.6%	-$101.3M-27.0%	-$79.7M-5.4%	-$75.6M+11.5%	-$85.5M-32.5%	-$64.5M

UNCY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$28.6M0.0%	-$28.6M-56.3%	-$18.3M-16.8%	-$15.7M-171.4%	-$5.8M-295.3%	-$1.5M
Capital Expenditures	$72K0.0%	$72K+500.0%	$12K+500.0%	$2K-93.1%	$29K	N/A
Free Cash Flow	-$28.6M0.0%	-$28.6M-56.6%	-$18.3M-16.9%	-$15.7M-170.1%	-$5.8M	N/A
Investing Cash Flow	-$72K0.0%	-$72K-500.0%	-$12K-500.0%	-$2K+93.1%	-$29K	N/A
Financing Cash Flow	$45.1M0.0%	$45.1M+63.7%	$27.5M+5947.3%	-$471K-102.1%	$22.4M+1449.5%	$1.4M
Dividends Paid	$1.1M0.0%	$1.1M+21.7%	$900K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.0M+29.2%	-$8.4M+5.4%	-$8.9M-36.0%	-$6.5M+29.2%	-$9.3M-46.4%	-$6.3M+2.1%	-$6.5M-45.4%	-$4.4M
Capital Expenditures	$2K-66.7%	$6K-62.5%	$16K-27.3%	$22K-8.3%	$24K+20.0%	$20K+233.3%	$6K	$0
Free Cash Flow	-$6.0M+29.2%	-$8.4M+5.5%	-$8.9M-35.8%	-$6.6M+29.2%	-$9.3M-46.3%	-$6.3M+1.9%	-$6.5M-45.6%	-$4.4M
Investing Cash Flow	-$2K+66.7%	-$6K+62.5%	-$16K+27.3%	-$22K+8.3%	-$24K-20.0%	-$20K-233.3%	-$6K	$0
Financing Cash Flow	$26.3M+139.7%	$11.0M+331.4%	$2.5M+597.5%	$365K+332.5%	-$157K+80.6%	-$811K-101.8%	$45.7M+22388.3%	-$205K
Dividends Paid	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UNCY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-3077.6%-1179.4pp	-1898.2%	N/A	N/A
Net Margin	N/A	N/A	-4525.0%-2626.2pp	-1898.8%	N/A	N/A
Return on Equity	N/A	-494.3%	N/A	N/A	-60.8%	N/A
Return on Assets	N/A	-116.0%+99.3pp	-215.2%+425.6pp	-640.8%-587.4pp	-53.4%+1056.4pp	-1109.8%
Current Ratio	N/A	1.28+0.5	0.76-0.0	0.81-7.9	8.75+8.7	0.07
Debt-to-Equity	N/A	3.26+8.0	-4.73+2.3	-7.05-7.2	0.14+1.2	-1.08
FCF Margin	N/A	N/A	-2710.4%-1064.4pp	-1645.9%	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-16.0%+23.2pp	-39.2%-44.3pp	5.1%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.9%+9.6pp	-21.5%-23.5pp	2.0%	N/A	-10.6%-32.7pp	22.1%+62.1pp	-40.0%	N/A
Current Ratio	3.83+1.7	2.18+0.5	1.64+0.4	1.28-2.3	3.61+0.2	3.37+1.7	1.71+0.9	0.76
Debt-to-Equity	0.35-0.5	0.83-0.7	1.48-1.8	3.26+5.6	-2.39+1.6	-4.01-0.9	-3.14+1.6	-4.73
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Vivani Medical VANI

$84.6M

Alterity Therapeutics Ltd ATHE

$63.1M

OS THERAPIES INCORPORATED OSTX

$49.7M

Anebulo Pharmaceuticals Inc ANEB

$14.7M

CEL-SCI Corp CVM

$27.2M

Frequently Asked Questions

Is Unicycive Therapeutics Inc profitable?

No, Unicycive Therapeutics Inc (UNCY) reported a net income of -$36.7M in fiscal year 2025.

What is Unicycive Therapeutics Inc's EBITDA?

Unicycive Therapeutics Inc (UNCY) had EBITDA of -$32.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Unicycive Therapeutics Inc's free cash flow?

Unicycive Therapeutics Inc (UNCY) generated -$28.6M in free cash flow during fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Unicycive Therapeutics Inc's operating cash flow?

Unicycive Therapeutics Inc (UNCY) generated -$28.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Unicycive Therapeutics Inc's capital expenditures?

Unicycive Therapeutics Inc (UNCY) invested $72K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Unicycive Therapeutics Inc spend on research and development?

Unicycive Therapeutics Inc (UNCY) invested $20.0M in research and development during fiscal year 2025.

How many shares does Unicycive Therapeutics Inc have outstanding?

Unicycive Therapeutics Inc (UNCY) had 25M shares outstanding as of fiscal year 2025.

Are Unicycive Therapeutics Inc's earnings high quality?

Unicycive Therapeutics Inc (UNCY) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Unicycive Therapeutics Inc cover its interest payments?

Unicycive Therapeutics Inc (UNCY) has an interest coverage ratio of -452.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.